AecorBio has successfully completed an equity financing round of $1.5m (£1.1m), enabling the company to investigate its lead peptide candidate FT-002a to treat advanced prostate cancer.  AecorBio, formerly known as HBC Immunology Inc, will use the financing to enable an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) in 2026 […]